Home > Cardiology > PCSK9 inhibitors may not be sufficient to curb atherosclerotic cardiovascular disease

PCSK9 inhibitors may not be sufficient to curb atherosclerotic cardiovascular disease

Journal
Journal of the American College of Cardiology
Reuters Health - 13/09/2021 - PCSK9 inhibitors may only partly address the portion of atherosclerotic cardiovascular disease risk mediated through the lipoprotein a Lp(a)/oxidized phospholipids (OxPLs) pathway, researchers say. They suggest that a targeted therapy such as pelacarsen may also be needed. "Our study showed, in an analysis of two small randomized clinical trials of different PCSK9 inhibitors, that OxPLs on apoB-containing lipoproteins were unchanged, despite expected reductions in low-density lipoprotein cholesterol (LDL-C) and Lp(a)," Dr. Sotirios Tsimikas of the University of California San Diego told Reuters Health by email. "Our finding may explain prior findings of persistent vascular inflammation in patients treated with PCSK9 inhibitors." "While secondary analyses of randomized clinical trials with PCSK9 inhibitors demonstrated risk reduction in patients with elevated Lp(a), likely due to a combination of LDL and Lp(a) lowering, persistently elev...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on